News Sentiment

KYTX sentiment intelligence

Kyverna Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.49 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-4.6% over one week, +5.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -4.6% Price reacting lower
Trend fit Trend inactive 5.3% over four weeks
Fair value 4.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 42
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 7
Stock Titan 4
GlobeNewswire 4
TradingKey 4
Seeking Alpha 3
Moomoo 3
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 21
Analyst action 7
Regulatory and legal 2
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 72
Finviz Direct company coverage

KYTX - Kyverna Therapeutics Inc Stock Price and Quote

This article provides comprehensive financial data, news, and analyst ratings for Kyverna Therapeutics Inc (KYTX). It details the company's stock performance, key financial metrics, recent executive appointments, and updates on its clinical trials and regulatory milestones, parti

Tone
Positive 65/100
Event
Analyst action
Published
05 Jun 2026 04:09
Source
Finviz
Investing.com Direct company coverage

H.C. Wainwright reiterates Kyverna stock rating on autoimmune data

H.C. Wainwright maintained a Buy rating and $25.00 price target for Kyverna Therapeutics (NASDAQ: KYTX) after updated Phase 1 trial data for its miv-cel treatment in rheumatoid arthritis showed significant disease activity reduction and B-cell depletion without high-grade adverse

Tone
Positive 86/100
Event
Analyst action
Published
04 Jun 2026 12:10
Source
Investing.com
TradingView Direct company coverage

KYTX: Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and market potential

Kyverna Therapeutics' (KYTX) Miv-cel CAR T therapy shows promising results in Stiff Person Syndrome (SPS) and generalized Myasthenia Gravis (gMG), demonstrating durable, drug-free remission with manageable side effects. The company is actively pursuing regulatory approval, with a

Tone
Positive 94/100
Event
Regulatory and legal
Published
03 Jun 2026 19:08
Source
TradingView
Investing.com Direct company coverage

Kyverna reports rheumatoid arthritis trial data at EULAR congress

Kyverna Therapeutics Inc. (NASDAQ:KYTX) presented updated Phase 1 data from its COMPARE trial for miv-cel in treatment-refractory rheumatoid arthritis at the EULAR congress, showing positive results in disease activity reduction and B-cell depletion without significant safety con

Tone
Positive 74/100
Event
Earnings
Published
03 Jun 2026 12:39
Source
Investing.com